Abstract
Polycythemia vera (PV) is a myeloproliferative disorder associated with an increased risk of cerebrovascular diseases. In this narrative review, we aimed to analyze the relationships between acute ischemic stroke and PV. We conducted a PubMed/Medline and Web of Sciences Database search using MeSH major terms. We found 75 articles and finally considered 12 case reports and 11 cohort studies. The ischemic stroke resulted as the first manifestation of PV in up to 16.2% of cases; the cumulative rate of cerebrovascular events was up to 5.5 per 100 persons per year and stroke accounted for 8.8% of all PV-related deaths; age, mutations, and a previous history of thrombosis were the main risk factors. The best approach to reduce stroke recurrence risk is unclear, even if some evidence suggests a potential role of lowering hematocrit below 45%. Ischemic stroke represents one of the most common PV manifestations but, despite their relationship, patients with both diseases have a very heterogeneous clinical course and management. PV-related strokes often remain underdiagnosed, especially for the low prevalence of PV. An early diagnosis could lead to prompt treatment with phlebotomy, cytoreduction, and low-dose aspirin to decrease the risk of recurrences. Clinicians should be aware of PV as a risk factor for stroke when approaching the differential diagnosis of cryptogenic strokes. An early diagnosis could positively influence patients’ management and clinical outcomes. Further studies are required to evaluate the role of PV treatments in the prevention of cerebrovascular disease.
-
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Research funding: None declared.
-
Conflict of interest statement: The authors declare no conflicts of interest regarding this article.
References
Abdel-Rahman, I. and Murphy, C. (2015). Recurrent ischaemic stroke unveils polycythaemia vera. BMJ Case Rep. 9: bcr2014207625, https://doi.org/10.1136/bcr-2014-207625.Search in Google Scholar PubMed PubMed Central
Arya, Y., Syal, A., Gupta, M., and Gaba, S. (2021). Advances in the treatment of polycythemia vera: trends in disease management. Cureus 30: e14193.10.7759/cureus.14193Search in Google Scholar PubMed PubMed Central
Barbui, T., Carobbio, A., Ghirardi, A., Masciulli, A., Rambaldi, A., and Vannucchi, A.M. (2017). No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on low-dose aspirin in polycythemia vera and cytoreductive therapy in polycythemia vera clinical trials. Haematologica 102: e219–e221, https://doi.org/10.3324/haematol.2017.165126.Search in Google Scholar PubMed PubMed Central
Barbui, T., Carobbio, A., Finazzi, G., Vannucchi, A.M., Barosi, G., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Salmoiraghi, S., Zilio, P., et al.. (2011). Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96: 315–318, https://doi.org/10.3324/haematol.2010.031070.Search in Google Scholar PubMed PubMed Central
Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Vannucchi, A.M., Besses, C., et al.. (2013). Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121: 4778–4781, https://doi.org/10.1182/blood-2013-01-478891.Search in Google Scholar PubMed PubMed Central
Berchie, P.O., Sarfo, F.S., Opare-Sem, O.K., and Ovbiagele, B. (2019). Recurrent stroke in a Ghanaian patient with polycythemia. J. Stroke Cerebrovasc. Dis. 28: 850–852, https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.032.Search in Google Scholar PubMed
Billakota, S. and El Husseini, N. (2014). Pearls & oy-sters: polycythemia vera presenting with ischemic strokes in multiple arterial territories. Neurology 82: e168–e170, https://doi.org/10.1212/wnl.0000000000000430.Search in Google Scholar
Cerquozzi, S., Barraco, D., Lasho, T., Finke, C., Hanson, C.A., Ketterling, R.P., Pardanani, A., Gangat, N., and Tefferi, A. (2017). Risk factors for arte-rial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Canc. J. 7: 662, https://doi.org/10.1038/s41408-017-0035-6.Search in Google Scholar PubMed PubMed Central
Crespo, A.M., Abraira, L., Guanyabens, N., Millán, M., Munuera, J., Dávalos, A., and López-Cancio, E. (2016). Recurrent stroke with rapid development of intracranial stenoses in polycythemia vera. J. Stroke Cerebrovasc. Dis. 25: e41–e43, https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.030.Search in Google Scholar PubMed
De Stefano, V., Za, T., Rossi, E., Vannucchi, A.M., Ruggeri, M., Elli, E., Micò, C., Tieghi, A., Cacciola, R.R., Santoro, C., et al.. (2008). Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors and effect of treatments. Haematologica 93: 372–380, https://doi.org/10.3324/haematol.12053.Search in Google Scholar PubMed
Dhrami-Gavazi, E., Lee, W., Horowitz, J.D., Odel, J., Mukkamala, S.K., Blumberg, D.M., Weiss, M., and Winn, B.J. (2015). JAK2 mutation-positive polycythemia vera presenting as central retinal artery occlusion. Retin. Cases Brief Rep. 9: 127–130, https://doi.org/10.1097/icb.0000000000000114.Search in Google Scholar PubMed
Finazzi, G. (2004). A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol. Biol. 52: 285–288, https://doi.org/10.1016/j.patbio.2004.02.007.Search in Google Scholar PubMed
Fleischman, A.G. and Tyner, J.W. (2013). Causal role for JAK2 V617F in thrombosis. Blood 122: 3705–3706, https://doi.org/10.1182/blood-2013-10-531665.Search in Google Scholar PubMed PubMed Central
Gori, T. (2011). Viscosity, platelet activation, and hematocrit: progress in understanding their relationship with clinical and subclinical vascular disease. Clin. Hemorheol. Microcirc. 49: 37–42, https://doi.org/10.3233/ch-2011-1455.Search in Google Scholar
Griesshammer, M., Kiladjian, J.J., and Besses, C. (2019). Thromboembolic events in polycythemia vera. Ann. Hematol. 98: 1071–1082, https://doi.org/10.1007/s00277-019-03625-x.Search in Google Scholar PubMed PubMed Central
Gruppo Italiano Studio Policitemia. (1995). Polycythemia vera: the natural history of 1213 patients followed for 20 years: Gruppo Italiano Studio Policitemia. Ann. Intern. Med. 123: 656–664, https://doi.org/10.7326/0003-4819-123-9-199511010-00003.Search in Google Scholar PubMed
Gruppo Italiano Studio Policitemia. (1997). Low-dose aspirin in polycythaemia vera: a pilot study. Br. J. Haematol. 97: 453–456, https://doi.org/10.1046/j.1365-2141.1997.362682.x.Search in Google Scholar PubMed
Gul, H.L., Lau, S.Y.M., Chan-Lam, D., and Ng, J.P. (2014). Vertebral artery thrombosis: a rare presentation of primary polycythaemia. Br. Med. J. Clin. Res. 3: 1–4, https://doi.org/10.1136/bcr-2013-201347.Search in Google Scholar PubMed PubMed Central
Hernández-Boluda, J.C., Arellano-Rodrigo, E., Cervantes, F., Alvarez-Larrán, A., Gómez, M., Barba, P., Mata, M.I., González-Porras, J.R., Ferrer-Marín, F., García-Gutiérrez, V., et al.. (2015). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann. Hematol. 94: 911–918, https://doi.org/10.1007/s00277-015-2330-2.Search in Google Scholar PubMed
Hosoya, H., Levine, J.J., Henry, D.H., and Goldberg, S. (2017). Double the trouble: acute coronary syndrome and ischemic stroke in polycythemia vera. Am. J. Med. 130: e237–e240, https://doi.org/10.1016/j.amjmed.2017.02.016.Search in Google Scholar PubMed
Kiladjian, J.J., Zachee, P., Hino, M., Pane, F., Masszi, T., Harrison, C.N., Mesa, R., Miller, C.B., Passamonti, F., Durrant, S., et al.. (2020). Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 7: e226–e237, https://doi.org/10.1016/s2352-3026(19)30207-8.Search in Google Scholar
Koennecke, H.C. and Bernarding, J. (2001). Diffusion-weighted magnetic resonance imaging in two patients with polycythemia rubra vera and early ischemic stroke. Eur. J. Neurol. 8: 273–277, https://doi.org/10.1046/j.1468-1331.2001.00217.x.Search in Google Scholar PubMed
Kurabayashi, K., Hishinuma, A., Uchida, R., Makita, S., and Majima, M. (2007). Delayed manifestation and slow progression of cerebral infarction caused by polycythemia rubra vera. Am. J. Med. Sci. 333: 317–320, https://doi.org/10.1097/maj.0b013e31805370a9.Search in Google Scholar PubMed
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., Barbui, T., and European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350: 114–124, https://doi.org/10.1056/nejmoa035572.Search in Google Scholar
Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R., and European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). (2007). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109: 2446–2452, https://doi.org/10.1182/blood-2006-08-042515.Search in Google Scholar PubMed
Lee, G. and Arcasoy, M.O. (2015). The clinical and laboratory evaluation of the patient with erythrocytosis. Eur. J. Intern. Med. 26: 297–302, https://doi.org/10.1016/j.ejim.2015.03.007.Search in Google Scholar PubMed
Lowe, G.D., Fowkes, F.G., Dawes, J., Donnan, P.T., Lennie, S.E., and Housley, E. (1993). Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh artery Study. Circulation 87: 1915–1920, https://doi.org/10.1161/01.cir.87.6.1915.Search in Google Scholar PubMed
Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., and Barbui, T. (2005). Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 23: 2224–2232, https://doi.org/10.1200/jco.2005.07.062.Search in Google Scholar PubMed
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al.. (2013). Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 368: 22–33, https://doi.org/10.1056/nejmoa1208500.Search in Google Scholar
Mehtap, Ö., Birtaş Ateşoğlu, E., Tarkun, P., Gönüllü, E., Keski, H., Topçu, Y., Uzülmez, N., Sünnetçi, D., and Hacıhanefioğlu, A. (2012). The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera. Turk. J. Hematol. 29: 162–169, https://doi.org/10.5505/tjh.2012.03780.Search in Google Scholar PubMed PubMed Central
Mesa, R., Vannucchi, A.M., Yacoub, A., Zachee, P., Garg, M., Lyons, R., Koschmieder, S., Rinaldi, C., Byrne, J., Hasan, Y., et al.. (2017). The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br. J. Haematol. 176: 76–85, https://doi.org/10.1111/bjh.14382.Search in Google Scholar
Michiels, J.J., Berneman, Z., Schroyens, W., Koudstaal, P.J., Lindemans, J., Neumann, H.A., and van Vliet, H.H. (2006). Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 17: 528–544, https://doi.org/10.1080/09537100600758677.Search in Google Scholar
Michiels, J.J., Berneman, Z., Gadisseur, A., Lam, K.H., De Raeve, H., and Schroyens, W. (2015). Aspirin-Responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2 V617F -positive essential thrombocythemia and polycythemia vera. Acta Haematol. 133: 56–63, https://doi.org/10.1159/000360388.Search in Google Scholar
Michiels, J.J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U., and van Vliet, H.H. (2006). The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin. Thromb. Hemost. 32: 589–604, https://doi.org/10.1055/s-2006-949664.Search in Google Scholar
Nezu, T., Aoki, S., Ochi, K., Sugihara, S., Takahashi, T., Hosomi, N., Maruyama, H., and Matsumoto, M. (2015). A case of recurrent ischemic stroke involving subacute, progressive intracranial cerebral arterial sclerosis prior to diagnosis with JAK2-mutated polycythemia vera. J. Stroke Cerebrovasc. Dis. 24: e4–e6, https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.08.040.Search in Google Scholar
Ong, E., Barraco, F., Nighoghossian, N., Praire, A., Desestret, V., Derex, L., Vighetto, A., and Biotti, D. (2016). Cerebrovascular events as presenting manifestations of myeloproliferative neoplasm. Rev. Neurol. 172: 703–708, https://doi.org/10.1016/j.neurol.2016.09.010.Search in Google Scholar
Passamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A.M., Sivgin, S., Bensasson, C., et al.. (2017). Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 18: 88–99, https://doi.org/10.1016/s1470-2045(16)30558-7.Search in Google Scholar
Pearce, J.M., Chandrasekera, C.P., and Ladusans, E.J. (1983). Lacunar infarcts in polycythaemia with raised packed cell volumes. Br. Med. J. 287: 935–936, https://doi.org/10.1136/bmj.287.6397.935.Search in Google Scholar
Pedersen, O.H., Larsen, M.L., Kristensen, S.D., Hvas, A.M., and Grove, E.L. (2017). Recurrent cardiovascular events despite antiplatelet therapy in a patient with polycythemia vera and accelerated platelet turnover. Am. J. Case Rep. 18: 945–948, https://doi.org/10.12659/ajcr.904148.Search in Google Scholar
Schwartz, K.A. (2005). Aspirin resistance: a review of methodologies, mechanisms and clinical utility. Adv. Clin. Chem. 42: 81–107, https://doi.org/10.1016/s0065-2423(06)42003-5.Search in Google Scholar
Stefanou, M.I., Richter, H., Härtig, F., Wang, Y., Örgel, A., Bender, B., Mengel, A., Ziemann, U., and Poli, S. (2019). Recurrent ischemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. Eur. J. Neurol. 26: 903–e64, https://doi.org/10.1111/ene.13907.Search in Google Scholar PubMed
Tanashyan, M.M., Shabalina, A.A., Roitman, E.V., Vavilova, T.V., and Kuznetsova, P.I. (2020). Thrombogenicity in patients with ischemic stroke and pre-existing polycythemia vera. Bull. RSMU 4: 47–53, https://doi.org/10.24075/brsmu.2020.052.Search in Google Scholar
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A.M., Rodeghiero, F., Randi, M.L., Vaidya, R., Cazzola, M., Rambaldi, A., et al.. (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27: 1874–1881, https://doi.org/10.1038/leu.2013.163.Search in Google Scholar PubMed PubMed Central
Tefferi, A. (2013). Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk- stratification, and management. Am. J. Hematol. 88: 507–516, https://doi.org/10.1002/ajh.23417.Search in Google Scholar PubMed
Tefferi, A. and Barbui, T. (2019). Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am. J. Hematol. 94: 133–143, https://doi.org/10.1002/ajh.25303.Search in Google Scholar PubMed
Trifan, G., Shafi, N., and Testai, F.D. (2018). Implications of janus kinase 2 mutation in embolic stroke of unknown source. J. Stroke Cerebrovasc. Dis. 27: 2572–2578, https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.052.Search in Google Scholar PubMed
Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R., et al.. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372: 426–435, https://doi.org/10.1056/nejmoa1409002.Search in Google Scholar PubMed PubMed Central
Zoraster, R.M. and Rison, R.A. (2013). Acute embolic cerebral ischemia as an initial presentation of polycythemia vera: a case report. J. Med. Case Rep. 7: 131, https://doi.org/10.1186/1752-1947-7-131.Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
